Flourish Research expands with acquisition of California clinical trials company
By Kyle Marshall | This article originally appeared on NCBiotech's blog.
Flourish Research, a multi-site clinical trials company based in Apex, has acquired a California clinical research facility.
The purchase of Diablo Clinical Research in Walnut Creek, Calif., expands Flourish’s therapeutic areas and geographic reach. With clinical trial sites in 10 states, Flourish enters the Bay Area market with the deal.
“For 30 years, Diablo has built its reputation as a premier regional site, delivering high participant diversity, top enrollment-to-target statistics and participant retention,” Flourish CEO Reinhold Schulz said in a news release.
Flourish serves biopharmaceutical and contract research organization (CRO) clients, primarily in three therapeutic focus areas: cardiovascular/metabolic/kidney, neuroscience, and infectious disease. Diablo focuses primarily on endocrinology, cardiovascular, and metabolic studies.
In 2024, Genstar Capital, a San Francisco private equity firm with $49 billion under management, acquired a majority interest in Flourish from NMS Capital. Also, last year, Flourish announced a significant expansion with its acquisition of Encore Research Group and its eight locations in Florida.
